Itrat Mehdi ( PMRC Research Centre, Jinnah Postgraduate Medical Centre, Karachi. )
Gastrointestinal tract is a major anatomical site for malignant tumours in humans1, with nearly one-fourth of cancer mortality attributed to them2. All these tumours, develop by a multistage carcinogenesis as evidenced by molecular, biological and genetic methods of analysis2. Most gastrointestinal tumours remain asymptomatic for long intervals and are far advanced, inoperable and many incurable at presentation or when diagnosed.2 They exhibitconsiderable differences in incidence, histology and prognosis among the component sites of the digestive tract thus influencing the treatment plan. An increased incidence of adenocarcinoma of oesophagus3, gastric cardia, small intestine and a changing relative frequency of colorectal cancers and the pattern of sites of involvement have been reported4,5. Rectal adenocarcinoma and squamous cell carcinoma of oesophagus have remained stable while the rate of gastric adenocarcinoma has decreased over the years6. Overall black and non-white races have a higher incidence of almost all gastrointestinal cancers with few exceptions like oesophageal adenocarcinoma and rectal adenocarcinoma6. Recently gastrointestinal tumours accounted for almost 25% of new cancer cases reported annually with an equally frequent mortality and an altered trend in the site of predilection6. As a group these tumours are refractoiy to therapy once metastasis has occurred, thus giving only a palliative intent to supportive therapy. In this issue of the Journal the article “Frequency of gastrointestinal tumours at a local hospital in Karachi” shows an increasing frequency of malignant gastrointestinal tumours from 1961 to 1992; from 9.1% to 17.1% in males and from 8.9% to 16% in females. A similar trend has been reported from other centres of the countiy7. This rise is significantly higher when adjusted forincrease in detection rate. These tumours, at present, are the most~frequent ones among males and second commonest in females. They exhibit a much lowerpeak age in ourpopulation as compared to Caucasians6. The peak age, incidence, histologic variance, prognosis and survival in our population are closer to black population abroad6. Almost 49% cases were between 35-54 years and 24% between 55-64 years of age. Small number of cases over 65 years is due to a lower life expectancy in our country.
Possible reasons for increase in malignant tumours are attributed to life pattern, diet and environment. There have been over the decades changes in the life style and pattern, a more stressful life both psychologically and physically; sexually transmitted diseases and sexual practices; use of more purified and low residue diet, increased use of food preservatives and chemical processing, increasing use of alcohol and tobacco; insurgence of newer chemicals and newly developed dmgs; water, air and environmental pollution; increased use of newly developed chemical fertilisers and insecticides in agriculture with undetermined longterm human toxicities; increasing nuclear contamination in atmosphere, more exposure to ionising radiation due to ozone depletion, newly emerging occupational hazards; changingviral universe with mutants and new oncogenic viral entities8-13. How these changes, factors and variables are translated in a catalyst for malignant change is yet to be explored in detail. There has been tremendous achievement in terms of diagnostic aids facilitating the accurate, early and prompt diagnosis of malignancy. Upper and lower GI endoscopy, endoscopic ultrasonography and ERCP (endoscopic retrograde cholangio-pancreatography) have made the direct visualization of oesophagus, stomach, duodenum, large intestine and pancreato-biliary tract a reality. This has also facilitated biopsy of previously unaccessible sites. Sonography has aided in analysing different aspects of solid masses and metastasis. CT scan and MRI have also helped tremendously in the diagnosis and evaluation of GI tumours and abdominal masses. Sonographic, CT scan, or MRI guided methods have made an accurate biopsy retrieval from the desirable site a reality. One has also witnessed improvement in old time barium study techniques and a great deal of advancements in vascular invasive diagnostic techniques. A new field of interest and of great help has been the tumour markers like carcinoembryonic antigen (CEA) in colorectal, gastric, pancreatic and hepatobilia7 carcinomas14 CA-50 and T-4 in oesophageal carcinoma1 polyamines, Lactate dehydrogenase and pepsinogen16-18; TAG-72 determination in colorectal carcinoma19 etc. in the diagnosis, monitoring, recurrence and treatment planning. The rise in gastrointestinal tumours over the years is too high to be explained on the basis of population growth and increased rate of detection even When influencing variables and other factors are accoutned for. The justifiable inference thus is that, the gastrointestinal tumours are increasing in reality. We have to be aware of it, be vigilant, keep eyes open, mind thinking and looking for it, exercise more screening and surveillance. Needless to say, one must emphasise on wider and extensive use of all available technology and investigational skills for an early tumour detection, a more successful treatment with sustainable remission and disease free survival. Lastly, an integrated primary and community health care is to be stressed strongly which can influence cancer related mortality and morbidity in our population.
1. Parkin, D.M., Muir, CS., Whelan, S.L. etal. Cancer incidence in five contments. Volume 6, Lyon, International agency for research on Cancer, 1992.
2. Haskell, CM., Lavey, R.S. and Ramming, K.P. Neoplasms of the gastrointestinal system, In ‘Cancer Treatment*; Eds, Charles MN. and Jonathan SB. 4th edition, Philadelphia, W.B. Saunders and Company, 1995, p.438.
3. Blot, W.J., Devesa, S.S., Kneller, R.W. et al. Rising incidence of adenocarcinoma of the esophagus and the gastric cardia. JAMA, I 992;265 :1287-89.
4. Axtell, L.M. and Chiazze, I. Changing relative frequency ofcancers of the colon and rectum in the United States. Cancer, 1966; 19:750-754.
5. Rhodes, J.B., Holmes, F.E and Clark, G.M. Changing distribution of primary cancers in the large bowel. JAMA, 1977;238:1641-43.
6. Rebecca, M Thomas and Leslie, H. Sobin. Gastrointestinal cancer. Cancer, 1995;75:54- 170.
7. PMRC. Multicentre tumour study report. Karachi, Pakistan Medical Research Council, 1977 and 1985.
8. Pitot, H.C Principles of carcinogenesis. Chemical; In ‘Cancer - Principles and practice of Oncology’, Eds. Vincent, T., Dc-Vita Jr., Samuel Hellman and Steven, A. Rosenberg, 3rd edition, Philadelphia, J.B. Lippincott Company, 1989;pp. 116-135.
9. Michael-Fry, R. J. Principles ofcarcinogenesis - Physical; In’ Cancer Principles and Practice of Oncology’, Eds. Vincent, T. De-Vita Jr., Samuel Hellman and Steven, A., Rosenberg, 3rd edition, Philadelphia, J.B. Lippincott Company, 1989; pp. 136- 148.
10. Peter, MN. Principles of carcinogenesis - Viral: In ‘Cancer - Principles and Practice of Oncology*, Eds. Vincent T. Dc-Vita Jr., Samuel Hellman and Steven A. Rosenberg; 3rd edition, Philadelphia, J.B Lippincott Company, 1989; pp. 149-166.
11. Peter, G. Principles of cancer prevention - Diet and nutrition: In ‘Cancer - Principles and Practice of Oncology’, Eds. Vincent, T Dc-Vita Jr., Samuel Hellman and Steven, A. Rosenberg; 3rd edition, Philadelphia, J.B. Lippincott Company, 1989, pp. 167- 180.
12. Wynder, EL. and Bross, I.J. A study of etiologic factors in cancer of the esophagus. Cancer, 1961 ;14:389-41 3.
13. Daling, JR., Weiss, N.S., Hislop, T.G. et al. Sexual practices, sexually transmitted diseases and the incidence of anal cancer. N. EngI. 3. Med., 1987;3 17:973-77.
14. Markham, N.I. and Sikora, K. Monoclonal antibodies and solid turmours, In’Tumour Markers in Clinical Practice - Concepts and Applications’; Eds. Daar,A.S., Oxford, Blackwell Scientific publications, 1987, pp. 497-521.
15. Haskell, C.M., Lavey, R.S. and Ramming, K.P. Esophagus, In ‘Cancer Treatment’; Eds. Charles M. Haskell and Jonathan S. Berth, 4th edition, Philadelphia, W.B. Saunders and Company, 1995, pp.439-451. .
16. Kubota, S., Yamasaki, Z., Yaoshimoto, M. et al. The value of urinary Polyamine Assay in Stomach Cancer. Cancer, 1985;56:1630- 1635.
17. Rogers, K., Roberts, G.M. and Williams, G.T. Gastric-juice enzymes An aid in the diagnosis of gastric cancer. Lancet, 1981 (May 23, 1981);1 124-1126.
18. Haskell, C.M., Lavey, R.S. and Ramming. K.P. Stomach, In’ Cancer Treatment’; Eds. Charles M. Haskell and Jonathon S. Berek, 4th edition, Philadelphia, W.B. Saunders and Company, 1995, pp. 452- 466.
19. Ryan, J.W. Immunoscintigraphy in primary colorectal cancer, Cancer, l993;7l :4217-4224.